Prostate cancer with neuroendocrine differentiation: Difference between revisions
Jump to navigation
Jump to search
tweak |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
'''Neuroendocrine carcinoma of the prostate''' redirect here. | '''Neuroendocrine carcinoma of the prostate''' redirect here. | ||
==General== | |||
*Treatment: platinum based therapy. | |||
==Subclassification== | ==Subclassification== | ||
| Line 13: | Line 16: | ||
==IHC== | ==IHC== | ||
*[[PSA]] typically negative in | *[[PSA]] typically negative in neuroendocrine carcinomas. | ||
==See also== | ==See also== | ||
*[[Prostate cancer]]. | *[[Prostate cancer]]. | ||
*[[Neuroendocrine carcinoma]]. | *[[Neuroendocrine carcinoma]]. | ||
*[[Paneth cell-like change of the prostate gland]]. | |||
==References== | ==References== | ||